Australian law firm files class action against Johnson & Johnson over ‘ineffective’ cold and flu medication
Do Cold Medicines Actually work? Class Action lawsuit Targets Johnson & Johnson
Table of Contents
- Do Cold Medicines Actually work? Class Action lawsuit Targets Johnson & Johnson
- Is Your Cold Medicine Actually Working? Lawsuit Claims Popular Decongestant is Ineffective
- Did your Cold Medicine Actually Work? Class Action Lawsuit Targets Popular Brands
- Popular Cold medicines Face Scrutiny as FDA Questions Effectiveness
- Is Your Cold Medicine Working? Lawsuit Questions Effectiveness of Popular decongestant
Millions of Americans may be unknowingly taking ineffective cold and flu medications, according to a new class action lawsuit filed against pharmaceutical giant Johnson & Johnson.
The lawsuit,brought by Australian law firm JGA Saddler,alleges that Johnson & Johnson falsely advertised popular over-the-counter medications like Codral Day and Night,Sudafed PE,and Benedryl PE as effective decongestants.At the heart of the lawsuit is phenylephrine,a key ingredient in these medications. Last year, the U.S. Food and Drug Administration (FDA) declared that phenylephrine, when taken orally in tablet form, is not effective at relieving nasal congestion.
despite this finding, Johnson & Johnson’s advertising for codral Day and Night states, “Phenylephrine helps to relieve blocked and runny noses”. Similarly, Sudafed PE packaging labels phenylephrine as a “nasal decongestant,” and the medication’s website claims it “provides fast, powerful relief from sinus pressure and nasal congestion”.
But Brisbane ear, nose, and throat specialist dr. Jo-Lyn McKenzie says the science doesn’t support these claims. “The data around phenylephrine is that its not effective when it’s taken orally,” she explains.Dr. McKenzie notes that phenylephrine can be an effective decongestant when used as a nasal spray, as it acts directly on the nasal passages. However, when swallowed, it is inactivated and loses its decongestant properties.
The use of phenylephrine in cold and flu medications increased after regulations were introduced in 2006 to restrict access to pseudoephedrine, a key ingredient in methamphetamine production.Pseudoephedrine was moved behind the counter at pharmacies,making it harder to obtain.
This lawsuit raises crucial questions about the effectiveness of common cold and flu medications and the clarity of pharmaceutical companies. It remains to be seen how Johnson & Johnson will respond to these allegations and what impact this case will have on the over-the-counter medication market.
Is Your Cold Medicine Actually Working? Lawsuit Claims Popular Decongestant is Ineffective
Millions of Americans reach for over-the-counter cold and flu medications every year, seeking relief from stuffy noses and sinus pressure. But what if the key ingredient in many popular decongestants isn’t actually doing anything?
That’s the central claim in a new class-action lawsuit filed against Johnson & Johnson, the maker of popular brands like Sudafed PE. The lawsuit alleges that the company knowingly replaced the effective decongestant pseudoephedrine with phenylephrine in many of its products, despite scientific evidence suggesting phenylephrine is ineffective when taken orally.
The switch came after the sale of pseudoephedrine, a key ingredient in methamphetamine production, was restricted in 2005. Johnson & Johnson replaced it with phenylephrine, allowing them to continue selling their products without the same restrictions.
“They use that treatment as an alternative to medications that do work,” said Dr. Sarah McKenzie, a leading expert on respiratory illnesses.
The lawsuit argues that consumers are being misled, believing they are purchasing effective cold and flu relief when, in reality, they are getting a placebo.
“Consumers expect these products to alleviate common symptoms of colds and flu, such as a blocked nose or sinus congestion,” said Rebecca Jancauskas, a lawyer representing the plaintiffs.
The lawsuit seeks compensation for consumers who purchased Sudafed PE and other Johnson & Johnson products containing phenylephrine, as well as an injunction requiring the company to stop marketing these products as effective decongestants.
Johnson & Johnson has denied the allegations, stating that their products are safe and effective when used as directed. The company maintains that phenylephrine is a proven decongestant and that their products provide relief from cold and flu symptoms.
The outcome of this lawsuit could have important implications for the over-the-counter medication industry, potentially leading to changes in labeling and marketing practices for decongestants. It also raises important questions about consumer trust and the responsibility of pharmaceutical companies to provide accurate facts about their products.
Did your Cold Medicine Actually Work? Class Action Lawsuit Targets Popular Brands
Millions of Americans may be eligible for compensation in a new class action lawsuit alleging that popular over-the-counter cold and flu medications containing phenylephrine are ineffective.
The lawsuit, filed by JGA Saddler law firm, targets Johnson & Johnson, the maker of well-known brands like Codral, Sudafed, and Benadryl. It claims that these products, which contain phenylephrine as a decongestant, have been misleading consumers for years by promising relief from nasal congestion that they don’t deliver.
“Many consumers report to us feeling duped, feeling misled by a company that they’ve trusted for many years,” said Rebecca Jancauskas, director at JGA Saddler.
The lawsuit argues that products containing phenylephrine are little more effective than paracetamol, which is frequently enough included in these medications.
“There’s a risk that the public loses confidence in medications, when they find out that trusted brand names like Codral, Sudafed and benadryl are ineffective and that the claims that have been made are simply unsubstantiated,” Jancauskas added.
The lawsuit comes on the heels of a proposal by the U.S. Food and Drug Administration (FDA) last year to remove oral phenylephrine from over-the-counter use due to its lack of effectiveness.
If the class action is triumphant, anyone who purchased Johnson & Johnson oral medications containing phenylephrine since 2005 could be eligible for compensation, potentially receiving the value of the products they purchased.
JGA Saddler is urging anyone who believes they may be affected to register for the class action.
Popular Cold medicines Face Scrutiny as FDA Questions Effectiveness
Millions of Americans rely on over-the-counter decongestants to relieve stuffy noses, but the effectiveness of a key ingredient is now under fire. The U.S. Food and Drug administration (FDA) is proposing that products containing phenylephrine as the sole active ingredient for nasal decongestion be removed from the market.
This move comes after the FDA reviewed decades of research and concluded that oral phenylephrine, commonly found in popular brands like sudafed PE and DayQuil, may not be effective at relieving nasal congestion.
The FDA’s proposal has sparked debate and concern among consumers and manufacturers alike.
“We are aware of the FDA’s proposal and are reviewing it carefully,” said a spokesperson for Johnson & Johnson, a major manufacturer of phenylephrine-containing products. “We stand behind the safety and quality of our products.”
The potential removal of phenylephrine products from shelves could have significant implications for the cold and flu season. many Americans turn to these medications for relief from stuffy noses, and alternative options may be limited or less effective.
The FDA’s proposal is currently open for public comment, and a final decision is expected in the coming months.
What This Means for You:
Check your medicine cabinet: If you regularly use over-the-counter decongestants containing phenylephrine, be aware of the potential changes.
Consider alternatives: Talk to your doctor or pharmacist about alternative decongestants, such as those containing pseudoephedrine, which requires a pharmacist’s assistance to purchase.
* Stay informed: Follow news updates on the FDA’s proposal and its potential impact on your access to cold and flu medications.
This developing story highlights the importance of ongoing scientific research and the FDA’s role in ensuring the safety and effectiveness of medications available to the public.
Is Your Cold Medicine Working? Lawsuit Questions Effectiveness of Popular decongestant
NewsDirectory3.com – Millions of Americans seeking relief from stuffy noses and the misery of colds and flu might potentially be getting shortchanged. A new class-action lawsuit filed against pharmaceutical giant Johnson & Johnson is calling into question the effectiveness of a key ingredient found in many popular over-the-counter decongestants.
At the heart of the lawsuit is phenylephrine, a common ingredient in medications like Sudafed PE and Johnson & Johnson’s Codral Day and Night. The lawsuit, brought by Australian firm JGA Saddler, alleges that Johnson & Johnson deceptively markets these products as effective decongestants despite growing scientific evidence suggesting or else.
This allegation comes on the heels of a 2022 declaration by the U.S. Food and Drug Administration (FDA) stating that oral phenylephrine is not effective at relieving nasal congestion.
Brisbane ear, nose, and throat specialist Dr. Jo-Lyn McKenzie confirms these concerns. “The data around phenylephrine is that it’s not effective when taken orally,” she explains. While phenylephrine can be an effective decongestant as a nasal spray, its effectiveness is lost when swallowed, she notes.
the shift to phenylephrine in over-the-counter cold and flu medications occurred after regulations in 2006 restricted access to pseudoephedrine, a key ingredient in methamphetamine production. Pseudoephedrine was moved behind the counter at pharmacies, making it harder to obtain.
This lawsuit raises critical questions about the practices of pharmaceutical companies and the truthfulness of their marketing claims. It also forces us to re-examine our reliance on common cold and flu medications.
“Consumers expect these products to alleviate common symptoms,” says Rebecca Jancauskas, a lawyer representing the plaintiffs in the lawsuit.
Johnson & Johnson denies the allegations, stating their products are safe and effective when used as directed and that phenylephrine is a proven decongestant.
The outcome of this lawsuit could have a meaningful impact on the over-the-counter medication industry, perhaps leading to changes in labeling and marketing practices. It also compels us to be more critical consumers, asking tough questions about the medications we put into our bodies.
NewsDirectory3.com will continue to follow this developing story and provide updates as they become available.